drugset
drugset / Trial / NCT05096494

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

NCT05096494 ↗

Phase 2 Completed 76 enrolled Scilex Pharmaceuticals, Inc. Worldwide Clinical Trials · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower back pain.

Timeline

Start
2022-04-29
Primary completion
2023-05-30
Completion
2023-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SP-103 Unknown — Topical

Indications

No indication recorded.